Level Four Advisory Services LLC Has $1.35 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Level Four Advisory Services LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,843 shares of the biopharmaceutical company’s stock after selling 879 shares during the period. Level Four Advisory Services LLC’s holdings in Bristol-Myers Squibb were worth $1,349,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. denkapparat Operations GmbH bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $834,000. Orion Portfolio Solutions LLC boosted its stake in shares of Bristol-Myers Squibb by 8.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 42,933 shares of the biopharmaceutical company’s stock worth $2,428,000 after acquiring an additional 3,436 shares during the period. Premier Fund Managers Ltd increased its holdings in shares of Bristol-Myers Squibb by 9.5% during the 4th quarter. Premier Fund Managers Ltd now owns 186,300 shares of the biopharmaceutical company’s stock worth $10,445,000 after acquiring an additional 16,100 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Bristol-Myers Squibb by 14.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,295,890 shares of the biopharmaceutical company’s stock valued at $73,296,000 after acquiring an additional 161,739 shares during the period. Finally, Frazier Financial Advisors LLC lifted its holdings in Bristol-Myers Squibb by 91.7% during the 4th quarter. Frazier Financial Advisors LLC now owns 694 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the acquisition, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Up 2.0 %

NYSE BMY opened at $60.10 on Friday. The business has a fifty day moving average price of $58.55 and a two-hundred day moving average price of $56.30. The stock has a market capitalization of $121.96 billion, a PE ratio of -13.60, a PEG ratio of 2.07 and a beta of 0.43. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Equities analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 4.13%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is -56.11%.

Analyst Ratings Changes

A number of analysts have recently issued reports on BMY shares. Cantor Fitzgerald raised their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Bank of America reaffirmed a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday, February 7th. Citigroup lifted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Truist Financial upped their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.